Nanjing Hicin Pharmaceutical Past Earnings Performance
Past criteria checks 4/6
Nanjing Hicin Pharmaceutical's earnings have been declining at an average annual rate of -1.8%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been declining at an average rate of 13.3% per year. Nanjing Hicin Pharmaceutical's return on equity is 3.7%, and it has net margins of 7.4%.
Key information
-1.8%
Earnings growth rate
-1.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -13.3% |
| Return on equity | 3.7% |
| Net Margin | 7.4% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Nanjing Hicin Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 505 | 37 | 299 | 49 |
| 31 Dec 23 | 518 | 36 | 315 | 47 |
| 30 Sep 23 | 525 | 35 | 331 | 36 |
| 30 Jun 23 | 520 | 34 | 331 | 31 |
| 31 Mar 23 | 493 | 32 | 318 | 16 |
| 01 Jan 23 | 526 | 32 | 330 | 18 |
| 30 Sep 22 | 504 | 278 | 330 | 17 |
| 30 Jun 22 | 529 | 282 | 351 | 16 |
| 31 Mar 22 | 567 | 285 | 386 | 19 |
| 01 Jan 22 | 578 | 286 | 405 | 22 |
| 30 Sep 21 | 612 | 35 | 411 | 27 |
| 30 Jun 21 | 647 | 40 | 421 | 31 |
| 31 Mar 21 | 702 | 52 | 428 | 31 |
| 31 Dec 20 | 706 | 55 | 422 | 32 |
| 30 Sep 20 | 788 | 68 | 458 | 36 |
| 30 Jun 20 | 845 | 81 | 499 | 32 |
| 31 Mar 20 | 880 | 92 | 536 | 33 |
| 31 Dec 19 | 925 | 97 | 567 | 36 |
| 30 Sep 19 | 871 | 98 | 548 | 38 |
| 30 Jun 19 | 826 | 95 | 525 | 41 |
| 31 Mar 19 | 759 | 89 | 483 | 46 |
| 31 Dec 18 | 712 | 83 | 465 | 38 |
| 30 Sep 18 | 679 | 82 | 441 | 33 |
| 30 Jun 18 | 624 | 77 | 376 | 50 |
| 31 Mar 18 | 543 | 75 | 314 | 35 |
| 31 Dec 17 | 455 | 66 | 244 | 31 |
| 30 Sep 17 | 388 | 60 | 191 | 22 |
| 30 Jun 17 | 333 | 53 | 168 | 0 |
| 31 Mar 17 | 305 | 48 | 146 | 0 |
| 31 Dec 16 | 281 | 45 | 130 | 0 |
| 30 Sep 16 | 262 | 48 | 174 | 0 |
| 31 Dec 15 | 221 | 40 | 85 | 0 |
| 31 Dec 14 | 198 | 34 | 73 | 0 |
| 31 Dec 13 | 170 | 33 | 55 | 0 |
Quality Earnings: 300584 has high quality earnings.
Growing Profit Margin: 300584's current net profit margins (7.4%) are higher than last year (6.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300584's earnings have declined by 1.8% per year over the past 5 years.
Accelerating Growth: 300584's earnings growth over the past year (16.9%) exceeds its 5-year average (-1.8% per year).
Earnings vs Industry: 300584 earnings growth over the past year (16.9%) exceeded the Pharmaceuticals industry -0.1%.
Return on Equity
High ROE: 300584's Return on Equity (3.7%) is considered low.